Evidence map›Paper›PMID 33691126›Full record

ArticleImmunity2021

Autocrine transforming growth factor β1 in regulatory T cell biology-gone but not missed.

Maria Velegraki, Mohammad Salem, Ephraim A Ansa-Addo, Bill X Wu, Zihai Li

Abstract readLetterComment
PubMed Publisher
In one paragraph

Article in Immunity, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed.

  1. Article
  2. Review
  3. Review
  4. TGF-β Regulation of T Cells.Annual review of immunology · 2023
    Review
  5. Article
  6. Review
  7. Review
  8. Article
  9. Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

5 authors.

Maria VelegrakiPelotonia Institute for Immuno-Oncology, The Ohio State University Comprehensive Cancer Center, Columbus, OH 43210, USA. Electronic address: maria.velegraki@osumc.edu.
Mohammad SalemDepartment of Microbiology and Immunology, Hollings Cancer Center, Medical University of South Carolina, Charleston, SC 29425, USA.
Ephraim A Ansa-AddoPelotonia Institute for Immuno-Oncology, The Ohio State University Comprehensive Cancer Center, Columbus, OH 43210, USA.
Bill X WuPelotonia Institute for Immuno-Oncology, The Ohio State University Comprehensive Cancer Center, Columbus, OH 43210, USA.
Zihai LiPelotonia Institute for Immuno-Oncology, The Ohio State University Comprehensive Cancer Center, Columbus, OH 43210, USA. Electronic address: zihai.li@osumc.edu.

Funding

Molecular chaperones and immune toleranceR01AI077283 · NIAID · UNIVERSITY OF CONNECTICUT SCH OF MED/DNT · PI LI, ZIHAI · 2009 to 2021
$3.7M
Integration of inflammation and cancer by molecular chaperoneR01CA213290 · NCI · OHIO STATE UNIVERSITY · PI LI, ZIHAI · 2017 to 2021
$860k
NCI NIH HHS R01 CA213290NIAID NIH HHS R01 AI077283
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

T-Lymphocytes, RegulatoryTransforming Growth Factor beta1BiologyReceptors, Transforming Growth Factor betaTransforming Growth Factor betaReceptors, Transforming Growth Factor betaTransforming Growth Factor betaTransforming Growth Factor beta1

Identifiers

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.